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Osteopontin expression in acute renal allograft rejection.
Background. Osteopontin (OPN) is a potent chemoattrac-
tant for mononuclear cells that is up-regulated in various inflam-
matory states of the kidney. The role of OPN and its expression
in human renal allograft rejection are unknown.
Methods. We examined by immunohistochemistry and in situ
hybridization, renal biopsies from patients with acute rejec-
tion (N = 22), protocol biopsies without rejection (N = 9),
and perioperative donor biopsies (N = 35) for intrarenal ex-
pression of OPN, and its correlation with clinical, laboratory,
and histopathologic parameters. In the rejection biopsies, inter-
stitial monocyte/macrophage infiltration, tubulointerstitial cell
proliferation/regeneration and apoptosis were investigated.
Results. In the majority of rejection biopsies, OPN expression
by proximal tubular epithelium was widespread, and tended to
be enhanced in the tubules surrounded by numerous inflam-
matory cells. Conversely, in patients that did not experience
episodes of rejection and in donor biopsies, OPN expression
by proximal tubules was nil or weak. OPN mRNA was colo-
calized with its translated protein in the renal tubular epithe-
lium. OPN expression positively correlated with the degree of
interstitial inflammation (P < 0.05), CD68+ monocyte infiltra-
tion (P < 0.01), Ki-67+ regenerating tubular and interstitial
cells (P < 0.05 and P < 0.005, respectively), but not with ter-
minal deoxynucleotidyl transferase (TdT)-mediated deoxyuri-
dine triphosphate (dUTP) nick-end labeling (TUNEL)-positive
apoptotic tubular cells.
Conclusion. These data suggest that inducible expression of
OPN in the tubular epithelium may have a pathogenic role in
acute renal allograft rejection by mediating interstitial mono-
cyte infiltration and possibly tubular regeneration.
Acute rejection produces significant monocytes accu-
mulation and activation in the graft, which is supposed to
be initiated by chemoattractants, including osteopontin
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(OPN), and has a pivotal role in the pathologic process
of rejection, acting directly or in concert with other arms
of the immune system.
OPN is a secreted phosphoprotein that has a num-
ber of diverse biologic functions, including cell adhesion,
migration, and signaling [1–3]. Originally isolated from
bone, but is also produced in the kidney, hence, its al-
ternative name uropontin. In rodent and human kidney,
OPN is constitutively expressed by distal tubular epithe-
lium [4–6]. OPN is a potent chemotactic molecule for
macrophages in vivo [7], and its up-regulated expression
by proximal tubular epithelial cells in association with
monocyte/macrophage infiltrates has been described in a
number of rodent models of renal injury [8–13], and in hu-
man renal diseases [14–16]. These studies have suggested
that OPN is likely to be a critical mediator of inflamma-
tion in specific diseases and injury states.
OPN may also function as a cell survival factor,
and may protect cells from undergoing apoptosis [17].
We have previously demonstrated a correlation be-
tween up-regulated OPN expression in proximal tubu-
lar epithelium and the proliferation and regeneration
of tubular epithelial cells during the recovery phase of
gentamicin-induced acute tubular necrosis [18]. Simi-
lar results have been shown in other toxic models [19]
and ischemic/reperfusion models of renal injury [20–22],
thereby lending further support for its renoprotective
role.
To elucidate the pathogenic significance of OPN and
its expression in acute renal allograft rejection, we exam-
ined by immunohistochemistry and in situ hybridization,
renal biopsies from patients with acute rejection, protocol
biopsies without rejection, and perioperative donor biop-
sies for intrarenal expression of OPN, and its correlation
with clinical, laboratory, and histopathologic parameters.
METHODS
Patients
Of 90 consecutive renal transplants performed at
Niigata University Hospital over the period (between
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May 1996 and August 2002), 32 patients suffered at least
one episode of clinical acute rejection in the first year af-
ter transplantation. Clinical acute rejection was suspected
in cases with acute allograft dysfunction with normal or
subtherapeutic levels of calcineurin inhibitors and nor-
mal findings by renal ultrasound. Of these, all patients
who had undergone a renal biopsy within 7 days of the on-
set of acute allograft dysfunction with (1) pathologically
confirmed acute rejection or borderline rejection accord-
ing to the standardized criteria of Banff working classifi-
cation of kidney transplant pathology and (2) adequate
formalin-fixed tissue available for immunohistochemistry
were included in this study (N = 20). The remaining cases
(12 of 32) with clinical acute rejection were excluded be-
cause six patients had not undergone a renal allograft
biopsy, three patients lacked the minimum criteria for
borderline rejection or in whom cyclosporine toxicity was
suspected, and three patients lacked adequate tissue to al-
low the studies described below. At the time of biopsy, 15
out of 20 patients were on triple-drug regimen, including
cyclosporine or tacrolimus with mycophenolate mofetil,
azathioprine or mizoribine and prednisolone. The other
five patients were on dual therapy with tacrolimus and
prednisolone. In 11 rejection cases, antirejection treat-
ment was initiated before graft biopsy based on clinical
suspicion.
In an attempt to stop steroid in renal transplant re-
cipients with early uncomplicated clinical course, the
practice to obtain protocol biopsies was introduced at
Niigata University Hospital in January 2003. Until March
2004, 16 protocol biopsies were done. Among them,
nine lacked the minimum criteria for borderline rejec-
tion, and served as a control group. The immunosup-
pressive regimen in the control group was comprised of
cyclosporine or tacrolimus, mycophenolate mofetil, and
prednisolone.
The study also included the perioperative biopsies of
transplanted kidneys (N = 35) of the same patients with
acute rejection, including 15 pairs of preimplantation
biopsies and 1-hour postreperfusion biopsies of the same
grafts and preimplantation biopsies of five additional
grafts. Normal human kidney specimens (N = 4) were
obtained from normal portions of kidneys resected for
localized neoplasms. Biopsies were performed only after
obtaining written informed consent from the patients.
Clinical data were gathered from our patient and
pathology databases and review of medical records (e.g.,
age, warm ischemic time, total ischemic time, and im-
munosuppressive therapy). Serum creatinine level, and
urinary protein excretion, of each patient were obtained
at the time of biopsy. Additionally, serum creatinine level
was obtained at two other points; the maximum serum
creatinine within 1 week of renal biopsy, and at 3 months
after the biopsy, an arbitrary date set up to signify a stable
outcome.
Antibodies
To examine the hypothesis that different molecular
forms of OPN, which may have diverse or even contrary
functions in normal or pathologic conditions, may be de-
tected by antibodies against different epitopes of OPN,
we tried two monoclonal antibodies which recognize dif-
ferent epitopes of human OPN (IBL, Fujioka, Japan).
O-17 is a rabbit IgG affinity-purified antibody directed
against the N-terminal of human OPN. 10A16 is a mouse
IgG1 antibody directed against a mid part of human OPN.
Their specific recognition of OPN has been characterized
by Western blotting [23]. Both antibodies demonstrated
identical patterns of staining, we therefore chose one of
these reagents, O-17, because of its specificity against the
most active N- terminal fragment which contains the cell-
binding arginine-glycine-aspartate (RGD) sequences to
perform the immunohistochemical staining in this article.
E29 (Dako, Glostrup, Denmark) is a murine mon-
oclonal IgG2a that is specific for epithelial membrane
antigen (EMA). EMA is known to be expressed by dis-
tal convoluted tubules, collecting ducts, and the thick as-
cending limb of the loop of Henle, and was shown to be
colocalized with OPN in human adult kidney [4].
PG-M1 (Dako) is a well-characterized murine mon-
oclonal antibody directed against the CD68 epitope
present on human monocytes and macrophages.
MIB-1 (Dako) is a well-established murine monoclonal
antibody for the demonstration of Ki-67 antigen, a nu-
clear protein preferentially expressed during cell prolif-
eration [24].
Immunohistochemistry
Serial sections of formalin-fixed, paraffin-embedded
biopsies of 3 lm thickness were prepared. For immuno-
histochemistry to detect OPN, the sections were first
deparaffinized and rehydrated, they were then heated
in a 0.01 mol/L citrate buffer (pH 6) under microwave
(5 minutes × 2) to unmask antigenicity. Subsequently,
they were treated with normal goat serum (Chemicon,
Temecula, CA, USA) at room temperature for 30 min-
utes to block nonspecific binding, and incubated with the
primary antibody, O-17 at a dilution of 1:50 over night
at 4◦C. After washing with phosphate-buffered saline
(PBS), OPN was detected using alkaline phosphatase
enhanced detection kit (red) (Ventana Medical Systems,
Tucson, AZ, USA).
Double immunohistochemistry was performed to de-
tect OPN in combination with EMA, Ki-67 and CD68.
Briefly, the sections were treated once more in a mi-
crowave oven, immersed in 3% H2O2 in methanol to
block the residual endogenous peroxidase, and in case
of CD68, incubated with trypsin (Wako Pure Chemical
Industries, Osaka, Japan) for 30 minutes at 37◦C. They
were sequentially incubated with normal goat serum,
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the primary antibody; either E29 (1:100), MIB-1 (1:50),
or PG-M1 (1:1) overnight at 4◦C, biotinylated goat
antimouse secondary antibody, and the avidin-biotin-
peroxidase [horseradish peroxidase (HRP)] complex
(Ventana Medical Systems). The sections were then visu-
alized with 3, 3′- diaminobenzidine (DAB) Dako, Carpin-
teria, CA, USA) to give a brown reaction product.
The cellular nuclei of the sections were counterstained
with hematoxylin, overslipped, and examined under light
microscopy.
Detection of apoptotic cells
Rejection specimens were examined for apopto-
sis using terminal deoxynucleotidyl transferase (TdT)-
mediated deoxyuridine triphosphate (dUTP) nick-end
labeling (TUNEL) of fragmented DNA as described
by Gavrieli, Sherman, and Ben-Sasson [25]. DNA la-
beling was performed using the TACS (Trevigen Apop-
totic Cell System) 2 TdT/DAB kit for apoptosis detection
in situ. Details are found in manufacturer’s instructions
(Trevigen, Gaithersburg, MD, USA). Briefly, paraffin-
embedded sections were deparaffinized in xylene, re-
hydrated through graded concentration of ethanol, and
washed with PBS for 10 minutes. To facilitate the pen-
etration of enzymes and biotinylated deoxyuridine, the
slides were subjected to 30 minutes of proteinase K
(10 lg/mL) digestion, and washed in deionized water two
times for 2 minutes. Endogenous peroxide was quenched
by immersion in 3% H2O2 in 40% methanol for 5 min-
utes. Then, the sections were rinsed in TdT labeling
buffer, incubated in the TdT labeling mixture at 37◦C for
1 hour. The reaction was stopped and the sections were
washed with PBS two times for 2 minutes. They were
subsequently covered with peroxidase-labeled streptoa-
vidin for 15 minutes, washed in PBS to remove un-
bound conjugate, and finally stained with DAB-H2O2
solution. Sections were counterstained with methyl-green
for 1 minutes, and coverslips were mounted.
To confirm the staining specificity, the TUNEL proce-
dure was modified as follows; for the positive controls,
TACS-Nuclease was added to the labeling mix to gener-
ate DNA break in every cell. Negative controls included
omission of TdT from buffer solution.
In situ hybridization
To amplify cDNA of human OPN coding region
(903 bp) by polymerase chain reaction (PCR), two
primers, 5′-ATGAGAATTGCAGTGATTTGC-3′ as a
forward primer and 5′-CGTAGAAGACTCCAGTTAA
TT-3′ as a reverse primer, were used. The PCR prod-
uct was cloned into a pGEM-T cloning vector (Promega,
Madison, WI, USA). The template was subsequently di-
gested with NdeI, and ligated with T4-ligase to obtain
OPN cDNA of 481 bp (from 422 to 903 bp).
The plasmid sample with the OPN cDNA (481 bp) was
linearized with NcoI as a sense probe and NdeI as an
antisense probe, respectively. In vitro transcription of the
cDNA was done using a digoxigenin (DIG) RNA labeling
kit (SP6/T7) (Roche Diagnostics, Penzberg, Germany).
500 ng of linearized plasmid was used as a template and
incubated with T7 DNA-dependent RNA polymerase for
2 hours to obtain an antisense probe. A SP6 promoter
was used to produce a sense probe, which was used as a
negative control.
In situ hybridization was done by the automated
mRNA in situ hybridization application (Ventana Med-
ical System) as described in [26]. Briefly, serial sec-
tions were automatically deparaffinized, fixed, and acid
treated. Then, the tissue sections were subjected to
cell conditioning and protease digestion. Hybridization
was performed with DIG-labeled OPN antisense probe
(30 ng/slide) at 60 for 6 hours, followed by incubation
with an alkaline phosphatase-conjugated anti-DIG anti-
body (Roche Diagnostics) at 37◦C for 1 hour, and the
signal was detected using a nitro blue tetrazolium chlo-
ride 5-bromo-4-cloro-3-indolyl phosphate toluidine salt
(NBT/BCIP) substrate solution for 3 hours.
Quantitative analysis
All counts and pathologic evaluations were performed
on coded slides without prior knowledge of the clin-
ical or histologic diagnosis. In each section, all fields
of the renal cortex were counted on a 1 cm2 eyepiece
graticule with 10 × 10 equidistant squares. Under high
magnification (×400), a minimum of 10 and a maxi-
mum of 20 consecutive nonoverlapping fields per section
were counted (average measured area, 3.5 ± 0.75 mm2).
On double-staining sections, the percentage area of
OPN-positive proximal (EMA-negative) and nonprox-
imal (EMA-positive) tubular cell segments in the total
area of proximal and nonproximal tubules were calcu-
lated, while the squares falling on glomeruli, Bowman’s
capsules, interstitium, or tubular lumen were excluded.
In addition, the intensity of staining in proximal tubu-
lar segments was graded semiquantitatively, as described
previously [27], with a scale of 0, no staining; 1+, weak
staining; 2+, moderate staining; and 3+, strong staining,
comparable to the observed intensity of staining in distal
tubular segments.
On separate serial sections, the quantification for
CD68-positive, Ki-67–positive, and apoptotic cells was
undertaken. Under high magnification (×400) equivalent
numbers of cortical graticule fields per section were ex-
amined, and the data are presented as the average num-
ber of CD68-positive cells per field; the percentage of
Ki-67–positive tubular and interstitial cells relative to
the total number of tubular and interstitial nuclei, re-
spectively, and as the percentage of apoptosis-positive
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Table 1. Baseline characteristics of the transplant recipientsa
Acute rejection No rejection
(N = 20) (N = 9)
Age years 34.7 ± 12.5 41.6 ± 13.2
Gender Male/female 15/5 5/4
Donor living/cadaver 19/1 9/0
Warm ischemic time minutes 6.7 ± 3.1 5.0 ± 1.3
Total ischemic time minutes 111.3 ± 101.1 94.9 ± 39.8
Number of biopsies/patients 22/20 9/9
Biopsy time days after
transplantation
68.0 ± 83.2 55.0 ± 71.9
Serum creatinine at biopsy mg/dL 2.1 ± 1.9 1.2 ± 0.7
Maximum serum creatinine within
a week of renal biopsy mg/dL
2.5 ± 2.3 NA
Serum creatinine 3 months after
biopsy mg/dL
1.6 ± 0.8 1.1 ± 0.9
Urine protein at biopsy g/day 0.3 ± 0.3 0.2 ± 0.2
Banff category Borderline = 11 <Borderline = 9
IA 7
IB 4
NA is non applicable.
aPlus-minus values stand for means ± SD were not significantly different
between the two groups.
tubular cells. The correlation analysis for OPN and CD68
or Ki-67 was undertaken on double-staining immunohis-
tochemistry sections for OPN protein and either CD68
or Ki-67 antigen.
Statistical analysis
Results were analyzed by a commercial software
package, SPSS 11.5 for Windows. We used unpaired
Student t test, Mann-Whitney U test, Kruskal-Wallis
H test, Wilcoxon single-rank test, and linear regression
analysis, as appropriate. P values less than 0.05 were used
as the criteria of statistically significant differences.
RESULTS
Table 1 shows the clinical profile of patients with acute
rejection versus control group. There was no significant
difference between the two groups with regards to age,
duration of ischemia, time of biopsy, serum creatinine,
and urinary protein. As for the donors, there were five
males and 15 females, aged 55.6 ± 10.8 years.
Expression of OPN protein and mRNA
To characterize the renal tubular epithelium, we car-
ried out double immunohistochemistry for OPN and
EMA as a marker of distal tubule. All renal biopsies (N =
70), including acute rejection, protocol, perioperative and
normal biopsies, were scored for both the percentage of
OPN-positive tubular area and the intensity of OPN im-
munostaining. Distal tubules served as an internal control
for OPN immunostaining, as they constitutively express
OPN protein, and did so in many, but not all, segments
of the distal nephron in every tissue studied.
In our study, all of the 22 rejection biopsies showed
tubulitis with interstitial infiltration but no vasculitis. The
high number of borderline rejections (N = 11) is proba-
bly because many of those biopsies were obtained after
antirejection treatment was initiated so that inflamma-
tory changes may have diminished in individuals that did
indeed have a significant rejection episodes [28].
In the majority of rejection biopsies that we exam-
ined, OPN expression by the proximal tubular epithelium
was widespread, exhibited low-to-moderate signal inten-
sity, and was predominantly observed in a distinct per-
inuclear pattern. The intensity of OPN immunostaining
was remarkably high in the degenerated proximal tubu-
lar cell segments and in the tubules surrounded by nu-
merous inflammatory cells. In addition, a few number of
the infiltrating cells within the interstitium demonstrated
positive OPN expression. Glomerular OPN expression
was occasionally observed within the glomerular tuft
and in the parietal epithelial cells lining Bowman’s cap-
sule. Two representative cases are shown in Figures 1A,
and 2.
Quantitative analysis showed that OPN-positive area
in the rejection biopsies was significantly higher than that
of protocol, preimplantaion, postreperfusion, and nor-
mal biopsies, in both proximal and distal tubules. The
signal intensity of OPN expression by proximal tubules,
a rough measure of the amount of protein present, was
significantly higher in the rejection biopsies when com-
pared with that of the other groups (Fig. 3), suggesting
that OPN expression was induced in the proximal and
distal tubular epithelium in acute rejection.
Regression analysis showed no significant correlation
between OPN expression and any of the three levels of
serum creatinine, as outlined in the Methods section, or
with the level of urinary protein excretion (rho = 0.05;
P > 0.05). Although no correlation could be found be-
tween OPN expression and the pathologic grade of rejec-
tion, OPN expression by proximal tubules significantly
correlated with the extent of interstitial inflammation
but not with tubulitis (Fig. 4). There were no significant
differences in the tubular expression of OPN, between
biopsies from patients receiving cyclosporine (N = 8) or
tacrolimus (N = 12) as a maintenance immunosuppres-
sive therapy, or between biopsies from those with and
without prior antirejection treatment.
The protocol biopsies used in this study had no promi-
nent mononuclear inflammatory cell infiltrate or tubuli-
tis. The perioperative biopsies generally had no specific
pathologic abnormality except for the cadavaric biopsy
specimen which showed features of acute tubular
necrosis.
In the protocol and perioperative biopsies, OPN was
uniformly expressed at high intensity by a subset of dis-
tal tubules, whereas no or weak expression of OPN by
proximal tubules (Fig. 1C). Quantitative analysis showed
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A B
C D
Fig. 1. Replicate tissue sections. (A and B) Sections with acute rejection demonstrating the colocalization of osteopontin (OPN) protein and
mRNA by immunohistochemistry and in situ hybridization. OPN protein is visualized by alkaline phosphatase (red) and OPN mRNA is hybridized
with digoxigenin-labeled OPN antisense probe. There is widespread expression of OPN by both proximal and distal tubules. Glomerular OPN
expression can be seen within the glomerular tuft and in the parietal epithelial cells lining Bowman’s capsule. (C and D) Sections from a protocol
biopsy without rejection showing OPN protein expression generally confined to the distal tubules, corresponding to the patterns of OPN synthesis
by in situ hybridization (magnification ×66).
A B
Fig. 2. Double immunohistochemistry. (A) Osteopontin (OPN) (red), and epithelial membrane antigen (EMA) (brown) in a rejection specimen,
demonstrating strong OPN expression in the tubular segments surrounded by numerous inflammatory cells. (B) Higher power view of the same
kidney (A), demonstrating the distinct perinuclear staining pattern of OPN [magnification ×66 (A) and ×160 (B)].
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Fig. 3. Quantitative analysis of osteopontin (OPN) expression. (A)
Proximal [epithelial membrane antigen (EMA)-negative] tubules. (B)
Distal (EMA-positive) tubules. (C) OPN score in acute rejection (N =
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that OPN-positive area in proximal tubules was not sig-
nificantly different between protocol, perioperative, or
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indeed significantly lower in the protocol biopsies when
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compared with that of perioperative biopsies but not with
normal biopsies (Fig. 3B).
In the perioperative biopsies, regression analysis be-
tween OPN expression and donor age did not show a
significant correlation. There was also no correlation be-
tween warm ischemic time and OPN expression in preim-
plantation biopsies or between total ischemic time and
OPN expression in postreperfusion biopsies.
To confirm the colocalization of OPN, protein and
mRNA replicate sections for immunohistochemistry and
in situ hybridization were used. In all sections that we ex-
amined, results of in situ hybridization for OPN mRNA
expression closely mirrored those seen by immunohisto-
chemistry. As can be seen in Figure 1, the patterns of lo-
calization of OPN protein and mRNA were very similar.
All sections examined with a sense probe were negative.
Correlation of OPN expression
and macrophage infiltrate
To examine the relationship between OPN and
monocyte/macrophage infiltration in acute rejection, we
performed immunohistochemistry for CD68 and double-
staining for OPN and CD68. In many cortical areas CD68-
positive cells tended to be localized in close proximity
with tubular segments that demonstrated positive OPN
expression (Fig. 5A). The quantitative data on the extent
of interstitial macrophage infiltration and OPN expres-
sion present in the rejection specimens used for this study
are presented as a scattergram in Figure 5B. In individ-
ual tissue section, the area of OPN-positive tubular seg-
ments positively correlated with the degree of interstitial
macrophage accumulation (rho = 0.546; P < 0.01).
Demonstration of Ki-67–positive cellular nuclei and its
relationship with OPN
To clarify the relationship between OPN expression
and cellular proliferation/regeneration, we carried out
immunohistochemistry for Ki-67 and double-staining
for OPN protein and Ki-67 antigen. Rejection biopsies
were scored independently for the percentage of Ki-67–
positive tubular and interstitial cells. In almost all acute
rejection specimens that we examined, Ki-67–positive
tubular cells were rare (mean 1.4%; range 0% to 6.3%),
whereas Ki-67–positive interstitial cells varied consider-
ably from 0.2% to 27% (mean 8.3%). Regression analysis
showed that the number of Ki-67–positive tubular epithe-
lial and interstitial cells was associated significantly with
OPN expression by proximal tubules (rho = 0.529, 0.639;
and P < 0.05, < 0.005, respectively) (Fig. 6A and B). The
result of double-staining, however, demonstrated that the
location of OPN expression had no distinct relationship
with that of tubular or interstitial cell proliferation in most
areas, but in some areas; the Ki-67–positive cells were ob-
served within or in the vicinity of OPN-positive tubules
(Fig. 6C).
Demonstration of cellular apoptosis and its relationship
with OPN
Apoptotic cells were detected in the tubular epithelia
in 18 cases of acute rejection (82%), with an overall rate of
2.5%, and range of 0% to 10.6%. TUNEL-positive cells
were almost exclusively observed in the distal tubular ep-
ithelial cells (Fig. 7), in contrast apoptosis was very rare
in the proximal epithelial cells. Apoptosis was occasion-
ally seen in the interstitial and glomerular compartment.
There was no significant correlation between TUNEL-
positive tubular cells and the extent of OPN expression
by either proximal or distal tubules. No correlation could
be found between TUNEL-positive tubular cells and the
extent of allograft dysfunction or the pathologic grade of
rejection.
DISCUSSION
OPN is well-known as a mediator of tubulointersti-
tial injury that accompanies glomerulonephritis [7, 8, 14–
16]; whereas its significance in renal allograft rejection
remains elusive. The present study clearly indicated that
OPN (protein and mRNA) expression significantly en-
hanced in acute rejection, and was correlated with inter-
stitial inflammation, macrophage infiltration, and cellular
proliferation but not with apoptosis.
Hudkins et al [27] [abstract; Hudkins KL, J Am Soc
Nephrol 11:A3497, 2000] found strong OPN protein and
mRNA expression by tubular epithelium in pretransplant
biopsies and in biopsies with cyclosporine toxicity without
an inflammatory cell infiltration, though the number of
donor biopsies available in their study was too small to
calculate a correlation.
The strong OPN expression in donor biopsies has been
assumed to be caused by ischemia, a known factor to in-
duce OPN expression in renal proximal tubular epithe-
lium [21, 29]. However, no data were available on the
association between the duration of ischemia and the
level of OPN expression.
In this study, we found no or weak expression of OPN
protein and mRNA by proximal tubules in the major-
ity of perioperative donor biopsies, and was independent
to the ischemic time. This is simply because almost all
of the studied donor biopsies, in contrast with those by
Hudkins et al [27], were from living donors; therefore, the
ischemic time was generally short. Constitutive expres-
sion of OPN by distal tubules was significantly higher
in the perioperative donor biopsies as compared with
that of protocol biopsies. This finding is unlikely to be
attributable solely to the fact that constitutive OPN ex-
pression by distal tubules varies widely in human adult
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A
Fig. 5. Double immunohistochemistry. (A)
Osteopontin (OPN) (red) and CD68+
macrophage (brown) in renal graft with
acute rejection, demonstrating the CD68+
macrophages in close proximity with tubules
expressing OPN (magnification ×100). (B)
Regression analysis showed OPN expression
in patients with acute rejection significantly
correlated with CD68+ monocyte infiltration
of adjacent interstitium.
C
Fig. 6. Regression analysis shows significant
correlation between osteopontin (OPN) ex-
pression. (A) Ki-67+ tubular cells, (B) Ki-
67+ interstitial cells in patients with acute
rejection. (C) Demonstrative case of acute
rejection showing the location Ki-67+ cells
(brown) was related to tubular OPN expres-
sion (red) in some areas (magnification ×100).
kidney [4]. Although no significant correlation could be
found between ischemia time and the level of OPN ex-
pression by distal tubules in the donor biopsies, it is likely
that the ischemia/reperfusion which might preferentially
induce OPN in the distal tubules. In a rat model of re-
nal ischemia, it has been shown that OPN expression by
distal tubules rapidly increased, as it was already highly
significant 12 hours after reperfusion, whereas proximal
tubules showed a delayed response [21].
In the majority of rejection biopsies that we exam-
ined, the presence of increased OPN immunostaining
that was accompanied by a concomitant OPN mRNA up-
regulation, not only in distal but also in proximal tubular
cells indicate OPN gene induction in these cells with a
possible role of OPN in acute rejection.
As the hallmark of acute rejection is tubulointersti-
tial inflammation, we hypothesize that some intrarenal
proinflammatory cytokines act via autocrine/paracrine
mechanism to stimulate OPN gene transcription and
expression. The consistently observed up-regulation of
OPN in areas of cellular infiltrate supports this hy-
pothesis. Classic mediators of acute inflammation such
as tumor necrosis factor-a (TNF-a), and interleukin-1b
(IL-1b) strongly induce OPN expression [30, 31].
Cytokine mRNA analysis on human renal allograft biop-
sies by a PCR-based assay confirmed the presence of
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these two mediators in acute cellular rejection [32], while
immunohistochemical studies demonstrate a marked
TNF-a expression by infiltrating inflammatory cells and
adjacent tubular cells in acute cellular rejection but not
in normal kidney [33, 34]. Other potential culprit that can
induce OPN up-regulation is endothelin-1 [35], which was
shown to be up-regulated on the tubular epithelial cells
in acute rejection [36, 37]. Taken together, these obser-
vations may explain the high level of OPN expression
in acute rejection. Nonetheless, other factors such as is-
chemia may also be involved.
The Banff working classification of renal transplant
pathology only focuses on the cellular inflammatory reac-
tions, including interstitial cell infiltration, tubulitis, and
arteritis. However, the extent of tubular cell injury is not
fully addressed in this classification. In this study, the de-
generated proximal tubular epithelial cells consistently
showed strong expression of OPN, suggesting that OPN
may have a complementary diagnostic value in assessing
the tubular cell injury in acute rejection.
Acute rejection is predominantly a cell mediated pro-
cess with CD4+ T lymphocytes playing a central role.
CD4+ T cells differentiate into two distinct T-helper cell
subsets, Th1 or Th2 cells, which have distinct profile of
cytokine production and thus mediate distinct functions.
Th1 cells are mainly involved in cell-mediated immunity,
whereas Th2 cells are associated with humoral immunity
[38]. OPN, by reacting with its receptors, influences the
polarization of T-helper cells to the Th1 or Th2 pheno-
types. OPN integrins interaction enhances Th1 whereas
OPN-CD44 interaction inhibits Th2 cytokines expression
[39, 40]. Cytokines secreted by the Th1 cells, such as
interferon-c (IFN-c) and IL-2 play a critical role in graft
rejection. Whether OPN directly affects those cytokines
in acute rejection in vivo remains to be determined.
The function of OPN in acute rejection appears to ex-
tend beyond being merely proinflammatory. Our data
showed significant relationship between OPN expression
and tubulointerstitial cell proliferation/regeneration,
suggesting a possible role of OPN in the repair of tubu-
lar injury. However, in contrast with our group’s previous
experimental model of acute tubular injury [18], double-
staining for OPN and Ki-67 antigen did not show a close
relationship in most areas. These contrasting results may
be explained by the different models and phases of renal
injury. In this study, biopsies were taken during the early
phase of acute rejection; therefore most of the tubular
cells have not yet been regenerating. Indeed most of the
Ki-67–positive cells were in the interstitial compartment.
Apoptosis is a cellular phenomenon generally found
within rejecting transplant [41]. Although the role and
mechanisms of apoptosis during rejection of allograft kid-
neys are not known, it appears likely that some apoptotic
effectors regulate the rejection process. The regulation of
antiapoptotic and proapoptotic oncogenes may vary with
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Fig. 7. A tissue section with acute rejec-
tion stained with a 2 terminal deoxynu-
cleotidyl transferase (TdT)/3, 3′- diaminoben-
zidine (DAB) kit for apoptosis detection
in situ, and methylene green counterstain-
ing. Terminal deoxynucleotidyl transferase
(TdT)-mediated deoxyuridine triphosphate
(dUTP) nick-end labeling (TUNEL) + sig-
nals (brown) were almost confined to the dis-
tal tubules, and were unrelated to interstitial
cell infiltration (magnification ×100).
cell types during the acute and recovery phase of acute
renal failure [42]. This may account for the frequently ob-
served apoptosis in the distal but not the proximal tubules
in acute rejection. OPN has antiapoptotic effect. In a re-
cent study, ischemic kidneys from OPN knockout mice
showed significantly enhanced apoptosis [43]. OPN ex-
pression did not correlate with the observed number of
apoptotic cells, indicating that OPN is probably an irrel-
evant regulator of apoptosis in acute rejection.
The available data on the significance of OPN expres-
sion in human renal diseases are still limited. In IgA
nephropathy, OPN has been shown to have a negative
impact on the prognosis [16]. In membranous nephropa-
thy, tubular expression of OPN was significantly higher in
patients with progressive disease [15]. In these two kinds
of chronic glomerulonephritis, the adverse prognostic sig-
nificance of OPN expression is probably caused by its sig-
nificant association with interstitial fibrosis. Overload of
tubular cells with filtered proteins has been shown to in-
duce OPN expression in the proximal tubular epithelium
in rat remnant kidney model in vivo, suggesting that pro-
teinuria may be a strong inducer of tubular OPN expres-
sion [44]. However, the correlation of proteinuria with
OPN expression in human renal diseases is rather con-
flicting [16, 45]. We could not find significant correlation
between OPN expression and renal function or urinary
protein excretion. This discrepancy between the clinical
and pathogenic significance of OPN expression may be
resulted from the antirejection treatment, the biopsy tim-
ing, or because of the diverse biologic functions of OPN.
The diversity of its function may limit the prospect of be-
ing a promising target for immunosuppressive therapy.
In the present study, we demonstrated the up-regulated
tubular expression of OPN at both the protein and
mRNA levels in biopsies from renal allograft with acute
rejection. OPN expression was correlated with intersti-
tial macrophage infiltration and cell proliferation in both
the tubular and interstitial compartments, supporting the
role of OPN in macrophage recruitment and the subse-
quent proliferation and regeneration of tubulointerstitial
cells in acute rejection.
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